Literature DB >> 7807296

Observations on bilateral simultaneous botulinum toxin injection in infantile esotropia.

K W McNeer1, R F Spencer, M G Tucker.   

Abstract

Botulinum toxin (BoTX) is an effective pharmacological alternative to the surgical management of strabismus in adults. In a previous study, we found that concurrent bilateral medial rectus muscle BoTX injections for infantile esotropia could produce stable ocular realignment without significant risk. No other investigators have used bilateral simultaneous BoTX injection. We report the results of bilateral simultaneous medial rectus BoTX injection in 57 infantile esotropia patients followed for a minimum of 12 months. The esotropic angle in 27 infantile esotropia patients under 12 months of age was reduced from 43 +/- 12 to 1 +/- 2 prism diopters. The esotropic angle in 30 infantile esotropia patients at a mean age of 24 months was reduced from 31 +/- 12 to 2 +/- 3 delta. Other variables including late onset of hyperopic refractive errors, dissociated vertical deviations, overacting oblique muscles, and consecutive exodeviations are evaluated. We regard BoTX as reliable therapy in infantile esotropia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7807296     DOI: 10.3928/0191-3913-19940701-05

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  3 in total

1.  Botulinum toxin injections combined with or without sodium hyaluronate in the absence of electromyography for the treatment of infantile esotropia: a pilot study.

Authors:  J Chen; D Deng; H Zhong; X Lin; Y Kang; H Wu; J Yan; G Mai
Journal:  Eye (Lond)       Date:  2012-12-14       Impact factor: 3.775

Review 2.  The role of drug treatment in children with strabismus and amblyopia.

Authors:  K I Chatzistefanou; M D Mills
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.930

3.  Comparison of botulinum toxin with surgery for the treatment of acute acquired comitant esotropia and its clinical characteristics.

Authors:  Li-Juan Lang; Yu Zhu; Zhi-Gang Li; Guang-Ying Zheng; Hai-Ying Peng; Jun-Bo Rong; Li-Min Xu
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.